OMERS ADMINISTRATION Corp Raises Holdings in Natera, Inc. (NASDAQ:NTRA)

OMERS ADMINISTRATION Corp raised its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 53.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,300 shares of the medical research company's stock after buying an additional 2,200 shares during the period. OMERS ADMINISTRATION Corp's holdings in Natera were worth $997,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Park Avenue Securities LLC grew its stake in shares of Natera by 12.3% in the 4th quarter. Park Avenue Securities LLC now owns 8,794 shares of the medical research company's stock worth $1,392,000 after acquiring an additional 961 shares in the last quarter. Avanza Fonder AB bought a new stake in Natera in the 4th quarter worth about $1,020,000. Merit Financial Group LLC purchased a new stake in Natera in the 4th quarter valued at about $552,000. Hanseatic Management Services Inc. lifted its position in shares of Natera by 12.0% during the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock worth $158,000 after buying an additional 107 shares in the last quarter. Finally, Atomi Financial Group Inc. purchased a new position in shares of Natera in the 4th quarter worth approximately $291,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Price Performance

Shares of Natera stock traded up $1.26 during trading on Tuesday, hitting $154.53. The stock had a trading volume of 879,370 shares, compared to its average volume of 1,385,285. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The firm has a market cap of $21.10 billion, a price-to-earnings ratio of -87.80 and a beta of 1.79. The business's 50-day moving average is $149.13 and its 200 day moving average is $157.15.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.56) EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Robert W. Baird lifted their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Barclays boosted their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Piper Sandler raised their price objective on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Royal Bank of Canada started coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $182.12.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 6,980 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the transaction, the chief executive officer now directly owns 185,182 shares in the company, valued at approximately $27,795,818.20. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 2,206 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $152.18, for a total value of $335,709.08. Following the sale, the insider now owns 139,280 shares in the company, valued at $21,195,630.40. The trade was a 1.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 152,436 shares of company stock valued at $22,019,079 in the last quarter. Corporate insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.